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Vitamin D deficiency and a CYP27B1-1260 promoter 
polymorphism are associated with chronic hepatitis C and 
poor response to interferon-alfa based therapy.
Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, 
Hassler A, Vermehren J, Herrmann E, Badenhoop K, Zeuzem 
S, Sarrazin C.
J Hepatol 2011;54:887-893
The prevalence of hepatitis C virus (HCV) infection in 
adults over age 40 is 1.29%, and the common HCV 
genotypes are Ib (40-59%) and 2a (33-52%) in Korea.
1,2 The 
best predictor of long-term response for chronic hepatitis C 
(CHC) to treatment is sustained virological response (SVR), 
defined as undetectable serum HCV RNA by PCR assay at 
24 weeks after cessation of therapy.
3 The standard of choice 
for HCV treatment is the combination of a pegylated interferon 
alpha and ribavirin (Peg/RBV). According to Korean data, 
the response rates to the recommended strategies have been 
observed to be high compared to Western data, but 20-40% 
of patients did not achieve an SVR.
4-6 Two major predictors 
of SVR are genotypes and viral load.
3 Other baseline 
predictors include the doses of Peg/RBV, gender, age, race, 
body weight, and fibrosis stage.
3 
Recently, two emerged predictors of response to antiviral 
treatment are interleukin-28B (IL-28B) rs12979860 C/T 
polymorphism and serum vitamin D concentration. IL-28B 
polymorphism is associated with SVR, and SVR rates are 
doubled in patients with the C/C homozygotes compared 
with the carrier of the T/T or T/C alleles.
7,8 However, this 
polymorphism represents a nonmodifiable factor that 
predicts SVR, and plays a smaller role in Korean patients 
due to high frequency of favorable allele.
9 Pre-treatment 
serum vitamin D concentrations affect SVR, and vitamin D 
deficiency shows low SVR in Peg/RBV treatment.
10,11 
Clinicians have increasing interest in vitamin D because it is 
easily modifiable and its supplementation may improve 
response to antiviral treatment.
12 Patients with CHC have 
higher incidence of severe vitamin D deficiency (25-hydroxy-
vitamin D, 25(OH)D <10 ng/mL) compared to the normal 
control (25% versus 12%, P<0.0001).
13 The prevalence of 
vitamin D deficiency (25(OH)D <20 ng/mL) was 47.3% of 
males and 64.5% of females,
14 but there was no report on 
that in patients with CHC in Korea. 
Vitamin D, as a regulatory factor of phosphorus and calcium 
absorption in intestine and renal reabsorption of calcium, plays a 
role in calcium metabolism. Through hydroxylation process of 
liver and kidney, vitamin D from the skin and diet is converted 
into the major circulating form, 25(OH)D, and then into the 
active form, 1,25-dihydroxyvitamin D (1,25(OH)D), respectively.
15 
In relation to vitamin D synthesis in the liver, mild to moderate 
liver dysfunction causes malabsorption of vitamin D and 
dysfunction of 90% or more results in inability to make sufficient Tae Yeob Kim. Role of vitamin D in chronic hepatitis C  171
25(OH)D.
15 Therefore, low vitamin D serum level in patients 
with CHC is correlated to severity of fibrosis.
11 In addition to 
CHC, 25(OH)D serum level is an independent predictor of risk 
for cancer, autoimmune disease, cardiovascular disease, and 
metabolic disease.
15 
1,25(OH)D is activated by binding with the vitamin D 
receptors (VDRs), which are found in almost immune cells 
such as CD4
+ and CD8
+ T cells, B cells, neutrophils, and 
antigen presenting cells, and is an important mediator of 
innate immune and adaptive immune systems.
16 1,25(OH)D 
enhances chemotactic and phagocytic responses of macrophage 
as well as induces antimicrobial actions with the upregulation 
cathelicidin via VDRs.
17 At the level of antigen presenting 
cells (like dendritic cells), 1,25(OH)D decreases antigen 
recognition by inhibited expression of MHC II molecules 
and co-stimulatory molecules (CD40, CD80, CD86). Further-
more, by suppressing production of IL-12 and IL-23, which 
are important Th1 and Th17 development, 1,25(OH)D 
inhibits the production of Th1 cytokines (IL-2 and IFN-γ) 
and Th17 cytokines (IL-17 and IL-23). A shift from Th1 to 
Th2 development stimulates Th2 cytokine production (IL-4). 
In addition, it induces regulatory T cells via modulation 
of dendritic cells and regulatory T cells and produce IL-10, 
which has the ability to interfere the development of the 
other Th subclasses. Finally, the action of 1,25(OH)D on B 
cells blocks proliferation, maturation to plasma cells, and 
immunoglobulin production.
16
Petta et al
11, by analyzing retrospectively a cohort of 197 
patients, detected an association between lower vitamin D serum 
levels and failure to achieve SVR. Of different isoforms of 
cytochrome P450 (CYP) involved in vitamin D metabolism, 
CYP2R1 and CYP27A1 exist in liver and CYP27B1 exists in 
kidney. Levels of CYP27A1, but not CYP2R1, were directly 
related to vitamin serum D levels and inversely correlated with 
necro-inflammation.
11 Bitetto et al
10 suggested that correction of 
vitamin D serum levels may play a complementary role to 
improve SVR in patients with difficult-to-treat HCV genotype 
and with IL-28B polymorphism. Based on the relationship 
between follow-up viral response rates and baseline 25(OH)D 
serum level, Bitetto et al
10 suggested that vitamin D plays an 
important role in early HCV decline after antiviral treatment. In 
two reports about additional effect of vitamin D on SVR in 
patients with CHC, Abu Mouth et al
18 showed vitamin D 
supplementation to Peg/RBV treatment significantly improved 
SVR in naïve genotype 1 patients (86% versus 43%, P<0.001), 
and Bitetto et al
12 showed the increase of SVR to antiviral 
treatment for recurrent hepatitis C (5/18 versus 5/27, P<0.02). 
The latter two studies have limited value due to small number of 
patients.
Together with these studies, Lange et al
13 retrospectively 
analyzed serum vitamin D levels and genetic polymorphisms in 
468 naïve patients with CHC. As above mentioned, 25(OH)D is 
converted to the 1,25(OH)D by 1-α-hydroxylase (CYP27B1) in 
the kidney and the biological activities of vitamin D are mainly 
mediated via the VDRs. Unlike other studies,
10,11 subjects were 
investigated about correlation between polymorphisms within 
genes of vitamin D cascade (VDR and CYP27B-1260 promoter) 
and serum vitamin D levels.
13 Three main findings are as follows. 
First, in similar to recent reports, the occurrence of vitamin D 
deficiency was more frequently observed in the patients (66%) 
than in the controls (41%). In addition, severe vitamin D 
deficiency was more observed in the patients (25%) than in the 
controls (12%). Second, pretreatment serum vitamin D level was 
related to high responsiveness of Peg/RBV treatment in patients 
with HCV genotype 2/3, but not in patients with HCV genotype 
1. This point is different from recent reports. Interestingly, in 
HCV genotype 1 patients, authors reported a positive association 
between SVR and 1-α-hydroxylase promoter polymorphism 
(CYP27B1-1260) and they suggested that 25(OH)D serum levels 
might not be an optimal predictor of SVR. Therefore, further 
researches are needed to investigate the effect of vitamin D 
according to race, polymorphism, and genotypes. Third, SVR 
rates were significantly higher in patients with CYP27B1-1260 
genotype AA or AC compared to CYP27B1-1260 genotype CC 
(77% and 65% versus 42%, respectively; P=0.02), but VDR 
polymorphism is not associated with SVR. This study has some 
limitations due to retrospective data, absence of on-treatment 
vitamin D serum levels, and absence of potential confounders. 
In conclusion, this study showed that the incidence of vitamin 
D deficiency is high in patients with CHC, vitamin D serum 
levels is linked to SVR, and a CYP27B-1260 promoter 
polymorphism is related with poor response to Peg/RBV 
treatment. To date, there are a few published reports on the role 
of vitamin D supplementation in patients with CHC and no 
domestic data on the relationship between vitamin D and CHC. 
Adding vitamin D to standard interferon therapy may increase 
SVR rates without serious adverse events. However, to prove 
these findings, well designed and large prospective studies are 
needed. 172  The Korean Journal of Hepatology Vol. 17. No. 2, June 2011
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